Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Peptide for Myocardial Infarction Proves to be Safe

07.04.2006


FIBREX Medical has successfully completed a first dose in man study with its lead product, the anti-inflammatory peptide FX06. FX06 is developed to prevent reperfusion injury, an undesired inflammatory reaction after acute myocardial infarction. The now completed clinical trial measured tolerability and pharmacokinetics of FX06 in healthy volunteers. The study confirmed the excellent safety profile of FX06 that has already been seen in experimental animal studies.



The clinical trial was performed at the medical University of Vienna, Austria. In total, 30 healthy participants received different doses of FX06 or a placebo, respectively. The trial’s results confirmed that even in high doses FX06 was very well tolerated with no adverse effects observed.

On the successful completion of this study Rainer Henning, CEO of FIBREX Medical, comments: "These very satisfying results allow us to progress rapidly with our development program for FX06. Already last year, in March 2005, we were able to demonstrate FX06’s efficacy in preventing reperfusion in multiple animal models of several species with a highly acclaimed paper in Nature Medicine. Now, just a year later we have finished the phase I trial and are ready to move on to the clinical trial phase II. The preparation for this proof of concept study in patients with acute myocardial infarction is well advanced. In fact, we will enroll the first patient in the second quarter of 2006". This phase II clinical trial, labeled the FIRE study, will prove FX06’s suitability for treating myocardial infarction in 140 patients in 20 centers in seven European countries. First results will become available in May 2007.


The rapid progress of FIBREX’s drug development program has also been made possible by the successful completion of a series A financing round in March 2005. Leading venture capitalists co-led by Atlas Venture and Global Life Science Ventures invested 10 million US-Dollar to this aim.

Till C. Jelitto | alfa
Further information:
http://www.fibrexmedical.com

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>